SUNPHARMA

Sun Pharmaceutical Industries is India’s largest pharmaceutical company with a strong presence in: Specialty medicines Chronic therapies Dermatology US generics market Emerging markets The company has been gradually shifting toward high-margin specialty products, which improves long-term growth visibility and profitability. Recent Financial Performance Recent quarterly results showed: Revenue growth remained strong Profit growth was healthy on a year-on-year basis Domestic India business performed well Specialty drug segment continued to support margins and growth However: Rising R&D and operating expenses created some pressure on margins US generic pricing pressure remains a concern for the sector Fundamental Analysis Strengths ✅ Market leader in Indian pharma sector ✅ Diversified product portfolio ✅ Strong brand value ✅ Consistent cash flow generation ✅ Strong domestic formulation business ✅ Expanding specialty drug business ✅ Defensive sector during market volatility ✅ Regular dividend-paying company Risks ⚠️ USFDA regulatory observations risk ⚠️ Pricing pressure in US generics market ⚠️ Currency fluctuations ⚠️ High competition in pharma sector ⚠️ Valuation currently not very cheap Technical Analysis Trend Analysis Long-term trend remains bullish Stock is trading above major moving averages Momentum remains positive overall Medium-term structure still strong unless major support breaks Important Levels Strong Support Zone: ₹1750 – ₹1780 Major Support: ₹1680 Resistance Zone: ₹1900 – ₹1920 Fresh breakout possible above resistance with strong volumes